Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Buy rating on Hansa Biopharma AB. The associated price target remains the same with SEK143.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Douglas Tsao has given his Buy rating due to a combination of factors surrounding Hansa Biopharma AB’s recent clinical trial success. The Phase 3 ConflideS trial demonstrated that imlifidase, the company’s lead product, achieved both primary and secondary endpoints with significant clinical outcomes. This trial involved highly sensitized kidney transplant patients and showed that those treated with imlifidase had notably better kidney function after 12 months compared to the control group.
These results are crucial as they align with established clinical guidelines and academic findings, suggesting a substantial improvement in patient outcomes. The positive data from this trial not only strengthens the case for FDA approval but also supports the potential for widespread adoption of imlifidase in the U.S. market. The achievement of dialysis independence as a secondary endpoint further underscores the therapeutic value of imlifidase, reinforcing the Buy rating as the company prepares for a Biologics License Application submission by the end of 2025.